Home » Stocks » Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. (VRTX)

Stock Price: $272.99 USD -0.35 (-0.13%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $274.00 +1.01 (0.37%) Aug 7, 7:05 PM

Stock Price Chart

Key Info

Market Cap 71.10B
Revenue (ttm) 5.40B
Net Income (ttm) 2.08B
Shares Out 260.47M
EPS (ttm) 7.92
PE Ratio 34.47
Forward PE 31.35
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $272.99
Previous Close $273.34
Change ($) -0.35
Change (%) -0.13%
Day's Open 273.48
Day's Range 269.95 - 277.20
Day's Volume 1,005,983
52-Week Range 165.23 - 306.08

More Stats

Market Cap 71.10B
Enterprise Value 66.18B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 260.47M
Float 260.07M
EPS (basic) 8.02
EPS (diluted) 7.92
FCF / Share 9.85
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.90%
FCF Yield 3.60%
Payout Ratio n/a
Shares Short 4.33M
Short Ratio 2.52
Short % of Float 1.56%
Beta 0.88
PE Ratio 34.47
Forward PE 31.35
P/FCF Ratio 27.81
PS Ratio 13.16
PB Ratio 9.47
Revenue 5.40B
Operating Income 2.10B
Net Income 2.08B
Free Cash Flow 2.56B
Net Cash 4.93B
Net Cash / Share 18.92
Gross Margin 34.44%
Operating Margin 38.95%
Profit Margin 38.50%
FCF Margin 47.32%
ROA 15.25%
ROE 33.06%
ROIC 79.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (26)

Buy 18
Overweight 0
Hold 8
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$307.14*
(12.51% upside)
Low
245
Current: $272.99
High
340
Target: 307.14
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue4,1633,0482,4891,7021,0325801,2121,5271,411143
Revenue Growth36.59%22.46%46.2%64.89%77.86%-52.11%-20.63%8.25%883.91%-
Gross Profit3,6152,6382,2141,4929085191,0821,2471,330131
Operating Income1,2026351239.94-467-692-61046.73114-696
Net Income1,1772,097263-112-556-739-445-10729.57-755
Shares Outstanding257254249245241235225212205200
Earnings Per Share4.518.091.04-0.46-2.31-3.14-1.98-0.500.14-3.77
EPS Growth-44.25%677.88%--------
Operating Cash Flow1,5691,270845236-365-573-60.67268144-635
Capital Expenditures-75.45-95.52-99.42-56.56-45.30-51.20-51.39-71.14-34.60-38.05
Free Cash Flow1,4941,175746180-411-624-112197109-673
Cash & Equivalents3,8083,1682,0891,4821,1431,3961,4651,4231,0551,066
Total Debt539582606841826825507697456537
Net Cash / Debt3,2702,5871,482642317571958726599529
Assets8,3186,2463,5462,8972,4992,3352,3192,7592,2041,725
Liabilities2,2331,8111,5041,5591,4051,2389631,5251,2391,221
Book Value6,0854,4352,0291,1579401,0751,356999787504
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vertex Pharmaceuticals, Inc.
Country United States
Employees 3,000
CEO Reshma Kewalramani

Stock Information

Ticker Symbol VRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VRTX
IPO Date July 24, 1991

Description

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.